Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.
You may also be interested in...
Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over
MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid
Israel Supreme Court Backs Sun Pharma For Taro Deal But Litigation May Not Be Over
MUMBAI - Sun Pharma's prolonged three-year battle to wrest control of Israeli generic drug maker Taro looks headed for a conclusion as the Israeli Supreme Court - after several months - allowed the Indian company to pursue purchase of outstanding shares, thereby dealing a blow to Taro's efforts to scuttle the takeover bid
Sun Feels The Heat As FDA Seizes Caraco Drugs; To Sign Consent Decree And Reset Guidance
MUMBAI - Days after U.S. FDA ordered seizure of 33 products from Caraco's Detroit-based manufacturing unit, its Indian parent Sun Pharma told investors that it will withdraw its earnings guidance and revise at a later date. Sun Pharma had set a guidance of 13-15 percent growth in 2009-10